
Cardiol Therapeutics Inc. (NASDAQ:CRDL – Free Report) – Equities research analysts at HC Wainwright reduced their FY2026 earnings per share estimates for Cardiol Therapeutics in a report issued on Friday, November 13th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.25) for the year, down from their previous estimate of ($0.24). HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.19) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ FY2028 earnings at $0.26 EPS, FY2029 earnings at $0.57 EPS and FY2030 earnings at $1.18 EPS.
CRDL has been the subject of a number of other research reports. Wall Street Zen cut shares of Cardiol Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Canaccord Genuity Group raised their target price on shares of Cardiol Therapeutics from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, August 17th. B. Riley Financial started coverage on shares of Cardiol Therapeutics in a research note on Wednesday, August 26th. They set a “buy” rating and a $11.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cardiol Therapeutics in a research note on Monday, September 21st. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.00.
Check Out Our Latest Analysis on Cardiol Therapeutics
Cardiol Therapeutics Stock Down 2.0%
CRDL stock opened at $0.98 on Tuesday. Cardiol Therapeutics has a 12 month low of $0.88 and a 12 month high of $2.34. The firm’s 50-day moving average is $1.39 and its 200 day moving average is $1.30.
Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02).
Institutional Trading of Cardiol Therapeutics
A number of hedge funds have recently bought and sold shares of the stock. Parallel Advisors LLC bought a new stake in Cardiol Therapeutics during the 3rd quarter valued at $32,000. Royal Bank of Canada increased its holdings in shares of Cardiol Therapeutics by 62.3% in the 1st quarter. Royal Bank of Canada now owns 21,648 shares of the company’s stock valued at $29,000 after acquiring an additional 8,306 shares during the period. Concurrent Investment Advisors LLC purchased a new position in shares of Cardiol Therapeutics in the 2nd quarter valued at $27,000. Cibc World Market Inc. bought a new position in shares of Cardiol Therapeutics in the 3rd quarter worth $55,000. Finally, State Street Corp bought a new position in shares of Cardiol Therapeutics in the 3rd quarter worth $166,000. Hedge funds and other institutional investors own 12.49% of the company’s stock.
About Cardiol Therapeutics
Cardiol Therapeutics is a Canadian biotechnology company developing therapies for inflammatory heart disease and other cardiovascular conditions. Its research focuses on treatments intended to address inflammation and related damage to the heart. The company’s lead candidate, CardiolRx, is a pharmaceutical-grade cannabidiol formulation under clinical investigation for conditions including myocarditis and pericarditis. Cardiol also has CRD-38, an investigational candidate being studied for potential use in heart failure.
Read More
- Five stocks we like better than Cardiol Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
